Identification of virulence associated regions rd1 and rd5 leading to improve vaccine of m. bovis bcg and m. microti
CA 2481318 C · Owner: Demangel, Caroline · Inventors: Cole, Stewart; Pym, Alexander S.; Demangel, Caroline
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to a strain of M. bovis BCG or M. microti wherein said strain has integrated part or all of the RD1 region responsible for enhanced immunogenicity of the tubercle bacilli especially the ESAT-6 and , CFP-10 genes. These strains will be referred as the M bovis BCG::RDI orM.microti::RD1 strains and are useful as a new improved vaccine for preventing tuberculosis and as a therapeutical product enhancing the stimulation of the immune system for the treatment of bladder cancer. These strains are also useful for the expression and presentation of heterologous antigens and molecule that are of therapeutic or prophylactic interest.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 1, 2003 and granted June 10, 2014. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 1, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 1, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.